ORIC earnings: next report 2026-08-11, real EPS beat/miss history, analyst consensus Buy, P/E -7.47. Updated 2026-07-23.
ORIC Pharmaceuticals (ORIC) Research Hub
ORIC Pharmaceuticals (ORIC) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 12.04 USD (-3.68%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -7.47, market cap 1.09B. This hub links to the full technical, earnings and options research available for ORIC.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 12.04 USD (-3.68%) |
| 52-week range | 8.13 USD – 14.68 USD |
| Trend regime | Range |
| 14-day RSI | 35 (Bearish) |
| Trailing P/E | -7.47 |
| Market cap | 1.09B |
| Dividend yield | 0.00% |
| Next earnings | 2026-08-11 |
Available research for ORIC
Covered Call on ORIC: how it works, illustrative setup around the real 12.04 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on ORIC: how it works, illustrative setup around the real 12.04 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on ORIC: how it works, illustrative setup around the real 12.04 USD price, max profit/loss, breakeven and when to use it. Educational.
ORIC technical analysis: range, last 12.04 USD, RSI 35, 52w range 8.13 USD–14.68 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is ORIC in?
ORIC Pharmaceuticals (ORIC) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is ORIC in an uptrend or downtrend?
As of 2026-09-11, ORIC is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is ORIC's trailing P/E ratio?
ORIC's trailing P/E is -7.47, with a market cap of 1.09B. See the earnings research page for full valuation detail.
When does ORIC next report earnings?
ORIC is next scheduled to report earnings on 2026-08-11, with a consensus EPS estimate of -0.36 USD.